ECSP088753A - Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano - Google Patents

Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano

Info

Publication number
ECSP088753A
ECSP088753A EC2008008753A ECSP088753A ECSP088753A EC SP088753 A ECSP088753 A EC SP088753A EC 2008008753 A EC2008008753 A EC 2008008753A EC SP088753 A ECSP088753 A EC SP088753A EC SP088753 A ECSP088753 A EC SP088753A
Authority
EC
Ecuador
Prior art keywords
growth factor
antibody against
epitelial
human type
tumor therapy
Prior art date
Application number
EC2008008753A
Other languages
English (en)
Inventor
Werner Scheuer
Thomas Friess
Max Hasmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37998279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088753(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088753A publication Critical patent/ECSP088753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método para el tratamiento de la enfermedad de cáncer de mama en un paciente en el que previamente ha fallado un tratamiento con un anticuerpo anti-VEGF, que comprende la administración al paciente de una cantidad terapéuticamente efectiva de un anticuerpo anti-HER2 mientras se continúa dicha terapia con anticuerpo anti-VEGF. La invención también proporciona los correspondientes artículos de elaboración y las composiciones farmacéuticas.
EC2008008753A 2006-03-22 2008-09-19 Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano ECSP088753A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06111523 2006-03-22
EP06021815 2006-10-18

Publications (1)

Publication Number Publication Date
ECSP088753A true ECSP088753A (es) 2008-10-31

Family

ID=37998279

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008753A ECSP088753A (es) 2006-03-22 2008-09-19 Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano

Country Status (24)

Country Link
US (4) US20070224203A1 (es)
EP (2) EP2364732B1 (es)
JP (2) JP5795463B2 (es)
KR (1) KR101089070B1 (es)
AR (1) AR059982A1 (es)
BR (1) BRPI0709025A2 (es)
CA (1) CA2645891A1 (es)
CR (1) CR10244A (es)
DK (2) DK2364732T3 (es)
EC (1) ECSP088753A (es)
ES (2) ES2392873T3 (es)
HU (1) HUE029615T2 (es)
IL (1) IL193675A0 (es)
MA (1) MA30290B1 (es)
MX (1) MX2008012014A (es)
MY (1) MY151449A (es)
NO (1) NO20083761L (es)
NZ (1) NZ570921A (es)
PL (2) PL2364732T3 (es)
RU (1) RU2538664C2 (es)
SG (1) SG170730A1 (es)
SI (2) SI1998805T1 (es)
TW (1) TW200812615A (es)
WO (1) WO2007107329A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CL2007002404A1 (es) * 2006-08-21 2008-04-18 Hoffmann La Roche Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
WO2012169822A2 (ko) * 2011-06-10 2012-12-13 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
MX368259B (es) 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
CN106794247B (zh) 2014-09-15 2022-12-02 豪夫迈·罗氏有限公司 抗体配制剂
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
TW202508629A (zh) 2017-01-17 2025-03-01 美商建南德克公司 皮下her2抗體調配物
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
WO1997049700A1 (en) 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
KR20060079258A (ko) 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
KR100816621B1 (ko) * 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
ID27562A (id) 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
DK1140173T4 (da) * 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
PL349839A1 (en) 1999-02-11 2002-09-23 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
IL144559A0 (en) 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
DE60040981D1 (de) 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
ES2282120T3 (es) 1999-06-25 2007-10-16 Genentech, Inc. Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2387351C (en) * 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
PT1106612E (pt) 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2003077841A2 (en) 2002-03-12 2003-09-25 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
EP2289942B1 (en) 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
US20040243207A1 (en) 2003-05-30 2004-12-02 Olson Donald R. Medical implant systems
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
AU2004261980A1 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

Also Published As

Publication number Publication date
CR10244A (es) 2008-10-29
RU2008141433A (ru) 2010-04-27
US20070224203A1 (en) 2007-09-27
EP1998805A1 (en) 2008-12-10
US20170239353A1 (en) 2017-08-24
NO20083761L (no) 2008-10-09
ES2392873T3 (es) 2012-12-14
JP2012207036A (ja) 2012-10-25
US20110064736A1 (en) 2011-03-17
BRPI0709025A2 (pt) 2011-06-21
KR101089070B1 (ko) 2011-12-05
CA2645891A1 (en) 2007-09-27
HK1131037A1 (en) 2010-01-15
JP5795463B2 (ja) 2015-10-14
IL193675A0 (en) 2011-08-01
EP2364732B1 (en) 2016-07-06
HUE029615T2 (en) 2017-03-28
KR20080096598A (ko) 2008-10-30
DK1998805T3 (da) 2012-10-08
MY151449A (en) 2014-05-30
WO2007107329A1 (en) 2007-09-27
US9090700B2 (en) 2015-07-28
ES2595238T3 (es) 2016-12-28
PL1998805T3 (pl) 2013-01-31
MX2008012014A (es) 2008-10-01
DK2364732T3 (en) 2016-10-10
MA30290B1 (fr) 2009-03-02
AR059982A1 (es) 2008-05-14
PL2364732T3 (pl) 2017-01-31
JP2009530333A (ja) 2009-08-27
SI1998805T1 (sl) 2012-12-31
SI2364732T1 (sl) 2016-12-30
NZ570921A (en) 2011-09-30
EP2364732A1 (en) 2011-09-14
EP1998805B1 (en) 2012-08-22
RU2538664C2 (ru) 2015-01-10
TW200812615A (en) 2008-03-16
AU2007229008A1 (en) 2007-09-27
US20150283238A1 (en) 2015-10-08
SG170730A1 (en) 2011-05-30

Similar Documents

Publication Publication Date Title
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
AR109246A2 (es) USO DE UN INMUNOCONJUGADO QUE COMPRENDE UN ANTICUERPO ANTI-ErbB2 PARA LA MANUFACTURA DE UN MEDICAMENTO
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
AR062840A1 (es) Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2)
DOP2017000177A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer
CO6150193A2 (es) Terapia tumoral con anticuerpo anti-vegf
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
JP2013543498A5 (es)
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
EP4477270A3 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
PE20160994A1 (es) Compuestos al receptor-3 del factor de crecimiento del fibroblasto (fgfr3) y metodos de tratamiento
PH12020551715A1 (en) Methods of treating cancer
CL2018000131A1 (es) Inmunoconjugados de il22
SG194735A1 (en) Compositions and methods for treating cancer
BR112018005494A2 (pt) composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença.
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
JOP20230112A1 (ar) أجسام مضادة لـ cd48، متقارنات الجسم المضاد مع العقار، واستخداماتها
UA95797C2 (ru) Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста
MX2023004601A (es) Trastuzumab emtansina para usarse en el tratamiento de cáncer de mama residual.
TH97405B (th) การบำบัดมะเร็งเนื้องอกด้วยแอนติบอดี anti-VEGF
TW202615106A (zh) 治療癌症之方法
Ghani Severe neutropenia and stomatitis: case report